Expand all sections

Abrocitinib

Cibinqo

Extended indication Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Abrocitinib
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Skin diseases
Extended indication Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis
Proprietary name Cibinqo
Manufacturer Pfizer
Mechanism of action JAK tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date June 2023
Expected Registration April 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.